Key clinical point: Barcelona Clinic Liver Cancer staging is applicable to recurrent HCC and should be used to formulate clinical stage criteria and develop treatment plans.
Major finding: The median time to tumor recurrence differed significantly among the BCLC staging groups A, B, and C (16 months, 10 months, and 6 months, respectively; P < 0.05). Median overall survival also differed significantly among groups A, B, and C (42 months, 22 months, and 13 months, respectively; P < 0.05).
Study details: The data come from a retrospective cohort study of 81 adults with recurrent HCC who were admitted to a single center between January 2013 and December 2017; they were divided into three groups based on the Barcelona Clinic Liver Cancer (BCLC) staging system to compare median time to tumor recurrence and median overall survival.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Yao S-Y et al. World J Clin Cases. 2021 Sep 26. doi: 10.12998/wjcc.v9.i27.8020.